Brookline upgraded Verrica Pharmaceuticals (VRCA) to Buy from Hold with a $17 price target
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRCA:
- Verrica Pharmaceuticals files to sell 14.76M shares of common stock for holders
- Verrica Pharmaceuticals: Hold Rating Amid Strategic Debt Retirement and Dilution Concerns
- Verrica Pharmaceuticals Secures $50M Financing Deal
- Verrica Pharmaceuticals announces private placement financing of $50M
- Verrica Pharmaceuticals Reports Strong Growth Amid Challenges